Researchers at MUSC Hollings Cancer Center published preclinical data showing that a monoclonal antibody targeting secreted frizzled‑related protein 2 (SFRP2) reduced primary triple‑negative breast cancer growth, blocked lung metastasis, and reprogrammed tumor‑associated macrophages in mouse models. The antibody reportedly restored immune activity, induced cancer cell death in chemotherapy‑resistant tumors, and suppressed angiogenesis. The work builds on decades of SFRP2 research and advances a candidate that could address residual unmet need in metastatic TNBC if translated to humans. Source: Breast Cancer Research publication and MUSC statements.